<DOC>
	<DOCNO>NCT02930109</DOCNO>
	<brief_summary>A phase I-II open label study PTX-200 combination cytarabine treatment relapse refractory acute leukemia .</brief_summary>
	<brief_title>A Study PTX-200 ( Triciribine ) Plus Cytarabine Refractory Relapsed Acute Leukemia</brief_title>
	<detailed_description>Study design : Phase I/II study The Phase I study open-label four increase dose level four 21-day cycle . Safety activity evaluate end cycle . The Phase II study open label administration recommend phase dose PTX-200 four 21-day cycle . PTX-200 co-administered cytarabine Phase I Phase II part study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Pathologic confirmation diagnosis AML , ALL ( acute lymphoblastic leukemia ) , blastphase CML ( chronic myelogenous leukemia ) Age ≥ 18 year ECOG Performance Status 02 Patients must able give adequate inform consent Hyperleukocytosis ≥ 30,000 leukemic blasts/µL blood ( hydroxyurea permit 24 hour prior begin study drug ) Uncontrolled Disseminated Intravascular Coagulation ( DIC ) Uncontrolled diabetes mellitus Active , uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>